Trevi Therapeutics, Inc. (TRVI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2700 |
| Open | 2.2400 |
| Bid | 2.0800 x 800 |
| Ask | 2.2400 x 1000 |
| Day's Range | 2.1600 - 2.3400 |
| 52 Week Range | 0.4600 - 3.7310 |
| Volume | |
| Avg. Volume | 720,882 |
| Market Cap | 57.379M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7560 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 |
- TipRanks
These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer
Earlier this month, the S&P 500 officially entered a bear market; its current year-to-date loss stands at 21%, and the NASDAQ, which has fallen faster and farther, stands at a 30% ytd loss. The rapid reversal not only put the bulls back in the corral, but also erased all of last year’s stock market gains, leading most analysts to start meditating on the prospects of recession. Among the headwinds they’re considering are the highest rates of inflation in over 40 years and in response, a sharp tur
- PR Newswire
Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention. In addition, Ms. Good will be participating in partnership meetings throughout the conference alongside Farrell Simon, SVP, Hea
- PR Newswire
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended March 31, 2022, as well as provided business updates.
